Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?
1 min read
The story
Novo Nordisk's oral semaglutide formulation has crossed 3 million prescriptions, a faster-than-expected ramp that signals real consumer appetite for a pill-based GLP-1 alternative to weekly injections. NVO's underlying financials remain robust — 81% gross margins, 33.1% net margins, and $23.03 diluted EPS on roughly $309B in revenue — yet the stock has been materially beaten down from its 2024 highs amid fears over Eli Lilly's tirzepatide dominance and potential biosimilar competition.
The 3M prescription milestone could mark an inflection point if oral GLP-1 adoption broadens the total addressable market rather than cannibalizing Ozempic/Wegovy injectable volumes. Key things to watch: oral semaglutide label expansion progress, any updated guidance from NVO management on pill vs. injectable mix, and whether the competitive gap with LLY on efficacy data narrows or widens into the next clinical readouts.
The case — both sides
With 81% gross margins, $23+ diluted EPS, and 3 million oral prescriptions already written, the market may be undervaluing NVO's franchise durability — particularly if the oral format expands the GLP-1 user base beyond injection-averse patients.
Lilly's tirzepatide has demonstrated superior weight-loss efficacy in head-to-head data, and NVO's revenue growth has already decelerated to 6.4% YoY, raising the possibility that the competitive threat to injectable Wegovy is more structural than the bull thesis allows.
The house read
Leans bullNVO has been heavily sold off on GLP-1 competition fears, but 3 million oral semaglutide prescriptions raises the question of whether the market has over-discounted the stock relative to its still-exceptional margin structure.
Wrong ifEli Lilly reports superior efficacy data for oral tirzepatide or accelerates biosimilar entry disrupts the oral semaglutide volume story and re-rates NVO lower.
Published read · research, not advice